Adagene  logo
Adagene ADAG
$ 4.32 8.27%

Annual report 2024
added 03-21-2026

report update icon

Adagene Interest Expense 2011-2026 | ADAG

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.
Includes:
  • Interest on bank loans
  • Interest on corporate bonds
  • Interest on leases
  • Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Adagene

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- 1.11 M 693 K 364 K 202 K 138 K 91.1 K - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
1.11 M 91.1 K 433 K

Interest Expense of other stocks in the Biotechnology industry

Issuer Interest Expense Price % 24h Market Cap Country
BioNTech SE BioNTech SE
BNTX
14.2 M $ 91.28 0.11 % $ 27.2 B germanyGermany
MorphoSys AG MorphoSys AG
MOR
4.66 M - 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
722 K - - $ 866 M chinaChina
Genfit SA Genfit SA
GNFT
4.68 M - 2.54 % $ 160 B franceFrance
Acorda Therapeutics Acorda Therapeutics
ACOR
31.5 M - -24.86 % $ 820 K usaUSA
Advaxis Advaxis
ADXS
28 K - -9.65 % $ 45.9 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
8.23 M - - $ 86.2 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
51 K - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
29.5 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
2.67 M - - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-5.79 M - 1.93 % $ 17.4 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
4.67 M - - $ 3.67 B usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
100 K $ 3.54 -20.81 % $ 238 B britainBritain
Akouos Akouos
AKUS
-1.72 M - 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
8 K - - $ 28.6 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-38 K - 3.16 % $ 1.9 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
5.2 M $ 330.34 3.6 % $ 43.3 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
476 K - - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
48 K - 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
1.44 M - 4.14 % $ 49.1 M usaUSA
Atreca Atreca
BCEL
3 K - -11.76 % $ 5.79 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-5.01 K - -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-4 K - - $ 10.1 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
-27 K - - $ 8.42 M usaUSA
Aptinyx Aptinyx
APTX
737 K - -39.0 % $ 4.57 M usaUSA
AbbVie AbbVie
ABBV
2.89 B $ 206.69 -1.01 % $ 366 B usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
6.55 M $ 4.09 -0.97 % $ 437 M usaUSA
Aravive Aravive
ARAV
2.84 M - -13.39 % $ 1.45 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
-2.71 M $ 3.39 -3.69 % $ 1.01 B canadaCanada
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
10.1 M $ 8.22 2.37 % $ 225 M israelIsrael
Ardelyx Ardelyx
ARDX
4.5 M $ 5.97 0.51 % $ 1.44 B usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
10.6 M - - $ 7.29 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
58 K $ 1.32 -4.35 % $ 339 M usaUSA